Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Deciphera Pharmaceuticals, Inc.    DCPH


Business Summary
Logo Deciphera Pharmaceuticals,
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Number of employees : 114 people.
Steven L. Hoerter20182019President, CEO & Independent Director
James A. Bristol, Dr.20182015Chairman
Thomas P. Kelly-2015Chief Financial Officer
Daniel L. Flynn, Dr.20182014Chief Scientific Officer
Stephen B. Ruddy, Dr.20182018Chief Technical Officer
Michael D. Taylor, Dr.20182019Director
Patricia L. Allen20182016Independent Director
Edward J. Benz, Dr.20182016Independent Director
John R. Martin-2015Independent Director
Michael Jay Ross, Dr.20182015Independent Director
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 50,647,539 33,903,620 66.9% 0 0.0% 66.9%
Brightstar Associates LLC 16,572,370 33.8%
New Leaf Venture Partners LLC 7,675,897 15.7%
OrbiMed Advisors LLC 3,618,171 7.38%
Millennium Management LLC 2,450,649 5.00%
Redmile Group LLC 2,223,376 4.54%
SV Health Investors LLC 1,836,674 3.75%
Polar Capital LLP 805,004 1.64%
The Vanguard Group, Inc. 761,339 1.55%
Viking Global Investors LP 735,898 1.50%
Janus Capital Management LLC 675,707 1.38%
Company contact information
Deciphera Pharmaceuticals, Inc.
500 Totten Pond Road
6th floor
Waltham, MA 02451

Phone : +1.781.209.6400
Fax : +1.781.830.2150
Web : http://www.deciphera.com